# GenScript Gene & Cell Engineering Virtual Summit

July 22nd, 2021. 11:00AM – 6:00PM EDT

## AGENDA

| Time | Keynote Speech | |
|---|---|---|
| 11:00-11:10 | **Introduction & Opening Remarks**<br>**Shiniu Wei**<br>CFO & VP of Investor Relations of GenScript | |
| 11:10-12:00 | **Keynote Presentation**<br>**Reprogramming Human T Cells with CRISPR**<br>**Alexander Marson, MD, PhD**<br>Director, Gladstone-UCSF Institute of Genomic Immunology | |
| 12:00-12:45 | **Track 1: Expanding CRISPR Toolbox**<br>**Building More Useful CRISPR-Cas Technologies**<br>**Ben Kleinstiver, PhD**<br>Assistant Professor, Massachusetts General Hospital and Harvard Medical School | **Track 2: Genome Editing in Cell and Gene Therapy**<br>**Genetic engineering approaches to support clinical applications of T-cell receptor libraries targeting oncogenic mutations**<br>**Gal Cafri, PhD**<br>Immunotherapy and Genetic Engineering Group Leader, Sheba Medical Center |
| 12:45-1:30 | **An Engineered AsCas12a nuclease facilitates the rapid generation of therapeutic cell medicines**<br>**John Zuris, PhD**<br>Associate Director, Editing Technologies at Editas Medicine | **CRISPR/Cas9-based genome editing for autologous CAR-T cell production**<br>**Ramarao Vepachedu, PhD**<br>Development Scientist IV, Leidos Biomedical Research, Inc. |
| 1:30-2:15 | **Operationalizing Genome Editing Across a Broad Range of Genomic and Cellular Targets**<br>**Shondra M. Pruett-Miller, PhD**<br>Director, St. Jude Children's Research Hospital Comprehensive Cancer Center | **Targeted Integration in Stem Cells**<br>**Matthew Porteus, MD, PhD**<br>Professor, Stanford University, School of Medicine |
| 2:15-2:45 | **Break** | |
| 2:45-3:30 | **Track 1: Expanding CRISPR Toolbox**<br>**Targeted DNA integration without double-strand breaks using CRISPR RNA-guided transposons**<br>**Sam Sternberg, PhD**<br>Assistant Professor, Department of Biochemistry and Molecular Biophysics, Columbia University | **Track 3: Enzyme and AAV Engineering**<br>**Library-selected AAV variants can effectively translate to non-human primates in the spinal cord and cochlea**<br>**Killian S. Hanlon, PhD**<br>Research Fellow, Harvard Medical School; Massachusetts General Hospital |
| 3:30-4:15 | **New delivery vehicles for gene editing enzymes**<br>**Niren Murthy, PhD**<br>Professor, Department of Bioengineering UC Berkeley- innovative Genomics Institute | **Improved chemistry by combining enzyme engineering, enzyme immobilization, and flow chemistry**<br>**Karla Camacho Soto, PhD**<br>Senior Scientist, Merck |
| 4:15-5:00 | **Clinical Scale Gene Editing for Cell and Gene Therapy Applications**<br>**Rama Shivakumar**<br>Manager of Technical Applications at MaxCyte Inc. | **Discovering the Next Generation AAV Vector Through Capsid Engineering and Expression Cassette Optimization**<br>**Ye Liu**<br>Senior Director of Gene Transfer Technologies, REGENXBIO Inc. |
| 5:00-5:45 | **Closing Keynote Presentation**<br>**Response to Second Generation CAR T Cell Therapy: It Takes (at least) Two to Tango**<br>**J Joseph Melenhorst, PhD**<br>Professor, Pathology and Laboratory Medicine, University of Pennsylvania and Director, Biomarker Program, Parker Institute for Cancer Immunotherapy, UPenn | |
| 5:45-6:00 | **Closing Remarks**<br>**Ray (Rui) Chen, PhD**<br>President of Life Science Group of GenScript | |

GenScript Make Research Easy | GenScript Gene & Cell Engineering Virtual Summit